JuRexMaximus

1.1K posts

JuRexMaximus

@JuryRex

Clinical Trials Professional • He/Him • 🇵🇭🇬🇧🇲🇽

Makati City Katılım Mart 2015

262 Takip Edilen72 Takipçiler

JuRexMaximus retweetledi

BiopharmIQ by Amp@BiopharmIQ·1d

$QURE surged +78% 🟢after a major FDA position shift on AMT-130 in Huntington’s disease. So what happened before the reversal? 🔍 We ran the due diligence through the BPIQ API: » FDA previously viewed the Ph1/2 data as insufficient to support accelerated approval » $QURE gapped down ~66%🔴 on that news » 3yr data now supports accelerated approval BLA » BLA targeted for Q3 2026 » First-ever RMAT in HD Market snapshot: » Last: $48.16 vs prior close $26.99 » 52-wk range: $8.73 to $71.50 Same data. Two opposite FDA calls. BPIQ API shows the full arc, not just the headline. Build it into your workflow: bpiq.com/bpiq-api

English

2.5K

JuRexMaximus retweetledi

BiopharmIQ by Amp@BiopharmIQ·1d

✅ $SPRO wins FDA approval • Utebzi (tebipenem pivoxil) approved for cUTI • First oral carbapenem approved in U.S. • Phase 3 data demonstrated non-inferiority to IV imipenem-cilastatin • Priority Review + Fast Track + QIDP

BiopharmIQ by Amp@BiopharmIQ

The first June’s PDUFA comes in 2 days: $SPRO and tebipenem HBr. BPIQ AI sees it as a classic binary: ~60–70% approval probability, but not clean! ✅strong unmet need (oral carbapenem for cUTI) ✅Phase 3 efficacy is solid ⚠️prior CRL (2022) still overhangs ⚠️potential for label restrictions If approved → meaningful re-rating If not → significant downside (single-asset story) High-risk, asymmetric setup into June 18.

English

4.8K

JuRexMaximus retweetledi

BiopharmIQ by Amp@BiopharmIQ·2d

$OTLK up 35% today! 📈 FDA accepted its resubmitted BLA for ONS-5010/LYTENAVA in wet AMD. Review is now on the clock, with a PDUFA target action date set for July 29, 2026. Want to track the exact FDA date and other upcoming PDUFAs? Check the comment below 👇

English

2.5K

JuRexMaximus retweetledi

BiopharmIQ by Amp@BiopharmIQ·1d

📢 Biotech Stock News 6/17 @ Open $QURE 75% BLA Submission Plan for AMT-130 $ELTX 23% ELI-002 Complete Responses $DYN 12% Expanded Debt Facility of $400M $CVM 10% Closing of Offering $ABCL 10% Collaboration w/ AbCellera $VSTM 8% Multiple Pipeline Updates $RZLT 7% Ersodetug Clinical Program Results $AVLN 7% Target Enrollment in Ph2b Trial $OCUL 6% FDA Alignment on AXPAXLI NDA $RIGL 6% VEPPANU Licensing Agreement $MIRA 4% Submits Ph2a for Ketamir-2 $JAZZ 1% Late-Breaking Data on Xywav® $ASRT 0% Merger Completion + Fundamental Change $ADPT -2% Prices $300M Convertible Notes Full details in the image + comments 👇 More biotech catalysts: app.bpiq.com/catalyst-calen…

Pharmdca@Pharmdca

$QURE Panic selloff on previous FDA Commissioner comments all in hindsight now. Stock dropped significantly just few months ago down to low teens. Those hindsight dips are up almost over 200%

English

2.9K

JuRexMaximus retweetledi

BiopharmIQ by Amp@BiopharmIQ·1d

📢 M&A News: Zydus Completes Acquisition of $ASRT Deal Terms » $23.50/sh all-cash (~$166.4M total consideration) » Premium: ~75.8% to unaffected close » $ASRT delisted from Nasdaq post-close Lead Asset » ROLVEDON® (eflapegrastim-xnst) » Type: long-acting G-CSF biologic » Indication: febrile neutropenia prevention in chemo-treated cancer pts » Stage: FDA-approved / marketed Commercial Signal » Once per chemotherapy cycle dosing » Adds oncology supportive-care portfolio » Brings U.S. specialty onco commercial infrastructure Strategic Fit » Expands Zydus’ U.S. specialty oncology footprint » Assertio now a wholly owned Zydus subsidiary

BiopharmIQ by Amp@BiopharmIQ

📢 M&A News: $GSK to Acquire $NUVL Deal Terms » $124/sh all-cash » ~$10.6B equity value » ~$9.4B net investment » Premium: 40% last close | 26% 30D VWAP Lead Assets » Zidesamtinib, ROS1 inhibitor » Neladalkib, ALK inhibitor » Indication: NSCLC » Stage: FDA review, 2026 PDUFA dates 🔍 BPIQ Lens » $GSK market cap: ~$101.5B » Deal size: ~10% of $GSK market cap » $NUVL up ~39% on the deal » BPIQ suspected mover: Zidesamtinib PDUFA, Sept. 18, 2026 Strategic Fit » Accelerates $GSK entry into lung cancer » Adds 2 potential best-in-class NSCLC assets » Complements GSK’s Ph3 B7-H3 ADC, Ris-Rez Timeline » Expected close: Q3 2026

English

2.4K

JuRexMaximus@JuryRex·1d

@louietbautista Booom

251

22.6K

JuRexMaximus retweetledi

Neil Stone@DrNeilStone·1 Haz

I've never been at a medical conference where the results have been greeted with a standing ovation Tremendous breakthrough in pancreatic cancer treatment Through science Hard work, rigorous research, clinical trials. Science Not the quack pseudoscience of social media

Rod Wong, MD@docrodwong

a standing ovation for daraxonrasib at asco. over 40k oncologists, entrepreneurs, investors, and patient advocates together celebrating revmed's breakthru in the fight against pancreatic cancer. u never forget these moments. it's what innovation is all about.

English

245

4.1K

20.5K

687.6K

JuRexMaximus retweetledi

Jake Wintermute 🧬/acc@SynBio1·2 Haz

A use case of scientific AI I hadn't considered - Retroactively comb the literature for obvious mistakes like this - Delete from the scientific corpus all the bad papers and all the papers citing them - Re-train AI on a better dataset than the one humans have been reading

Sholto David@addictedtoigno1

Today I'm posting a new blog about an astonishing scientific own goal. Hundreds of papers have reported using a completely wrong antibody to investigate the tumor suppressor p16. This mistake has happened because scientists have muddled the names of two proteins 🧵

English

JuRexMaximus retweetledi

Sholto David@addictedtoigno1·2 Haz

English

132

634

95.5K

JuRexMaximus@JuryRex·11 May

@ABSCBNNews Lol suot suot pa kayo ng Filipino inspired damit para mapakita na "representation kayo ng Pinas" ulol.

Filipino

974

ABS-CBN News@ABSCBNNews·11 May

Nanindigan si Senate President Alan Peter Cayetano na walang kaugnayan ang impeachment ni Vice President Sara Duterte sa pagpapalit ng liderato ng Senado.

Filipino

1.3K

156

1.7K

420.3K

JuRexMaximus@JuryRex·11 May

@PhilippineStar Di ka na diyan lalabas Bato good luck hehe Itong mga Chinador na to nakoo hehe

Filipino

397

The Philippine Star@PhilippineStar·11 May

'NAGPAPAKITA AKO DITO, HINARANG AKO NG MGA NBI' Senator Ronald "Bato" dela Rosa aired his dismay after the National Bureau of Investigation (NBI) allegedly tried to stop him from joining the Senate session on Monday. "Kung ako'y absent, hinahanap ninyo ako. sumusweldo, hindi nagpapakita. Ngayon, nagpapakita ako dito, hinarang ako ng mga NBI," he stated. This is Dela Rosa's first appearance at the Senate after months of absence. WATCH: youtube.com/watch?v=KzrO0P…

YouTube

Filipino

8.3K

JuRexMaximus@JuryRex·17 Nis

@AngelOfPeaceTea @jaicabajar Sinayang mo 18mins ng buhay ko para panuorin yung hearing FAKE NEWS po ikaw. Kitang kita na denied ang petition niya at pinapabalik yung ~73 million. Source: youtu.be/Ffh9VPtGBM0?si…

YouTube

Filipino

Christ Trucis@AngelOfPeaceTea·15 Nis

@jaicabajar Ay paano mo na laman na chatgpt? may proof ka ba? hahaha

Cece 🇵🇭@MamaPiaya

Paulit-ulit na to ha.

Filipino

1.3K

Jai Cabajar@jaicabajar·15 Nis

Honestly di ko gets bakit aayaw dito. Kung DDS ako, i-pupush ko pa to para manahimik lahat ng tao kung talagang inosente siya. And don’t tell me na marami namang problema ang Pilipinas na dapat asikasuhin. Tandaan niyong pinasara ang ABS during the pandemic at tuwang tuwa kayo

Inquirer@inquirerdotnet

A majority of Filipinos, or 69 percent, support an impeachment trial against Vice President Sara Duterte, according to OCTA Research’s 2026 Tugon ng Masa survey. READ MORE: inqnews.net/majoritybackim…

Filipino

412

2.2K

79.7K

JuRexMaximus@JuryRex·17 Nis

@MamaPiaya Sinayang mo 18mins ng buhay ko para panuorin yung hearing FAKE NEWS ka!!! Kitang kita na denied ang petition niya at pinapabalik ang ~73 million. Source: youtu.be/Ffh9VPtGBM0?si…

YouTube